Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV-CHEP for Adult T-Cell Leukemia/Lymphoma
NCT03264131Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in adult T-cell leukemia-lymphoma (ATLL), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Oct 2018; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT03264131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264131.